GENTA INC DE/ Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-11: Form 8-K; Period of report 2009-12-11; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2009-12-02: Form 8-K; Period of report 2009-12-02; Description 8.01 Other Events; Details 8.01.
- 2009-11-16: Form 8-K; Period of report 2009-11-16; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2009-11-16: Form 8-K; Period of report 2009-11-16; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-11 | 8-K | 2009-12-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v168827_8k.htm |
| 2009-12-02 | 8-K | 2009-12-02 | 8.01 Other Events | 8.01 On December 2, 2009, Genta Incorporated, (the Company), announced that the Company will supply Ganite® (gallium nitrate injection) for a new clinical trial that will be initiated in patients with cystic fibrosis (CF) who may develop serious infections. | v168061_8k.htm |
| 2009-11-16 | 8-K | 2009-11-16 | 2.02 Results of Operations and Financial Condition | 2.02 On November 16, 2009, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter and nine months ended September 30, 2009. | v166451_8k.htm |
| 2009-11-16 | 8-K | 2009-11-16 | 8.01 Other Events | 8.01 On November 16, 2009, Genta Incorporated, (the Company), announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. | v166421_8k.htm |
| 2009-10-29 | 8-K | 2009-10-29 | 8.01 Other Events | 8.01 On October 29, 2009, Genta Incorporated, (the Company), announced that top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. | v164099_8k.htm |
| 2009-10-07 | 8-K | 2009-10-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v162323_8k.htm |
| 2009-09-11 | 8-K | 2009-09-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 16, 2009 each individual who was being nominated for re-election as a Director at the Annual Meeting to continue in service as a non-employee Board member following such meeting and tendered for cancellation his outstanding equity awards pursuant to the Company's Equity Award Exchange Offer was automatically granted an award of 695,658 restricted stock units. | v160058_8k.htm |
| 2009-09-09 | 8-K | 2009-09-04 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | v160029_8k.htm |
| 2009-09-04 | 8-K | 2009-09-04 | 8.01 Other Events | 8.01 Genta Incorporated (the “Company”) is reissuing its historical consolidated financial statements included in its Annual Report on Form 10-K for the years ended December 31, 2008, 2007 and 2006 as amended (“2008 Form 10-K”) as filed with the Securities and Exchange Commission (“SEC”) on February 13, 2009 and as amended on April 6, 2009 to show the effects of the subsequent reverse stock split at a ratio of one for fifty shares implemented by the Company on June 26, 2009. | v159851_8k.htm |
| 2009-08-26 | 8-K | 2009-08-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On March 19, 2009, Martin J. Driscoll informed Genta Incorporated, a Delaware Company (the “Company”), of his decision not to stand for re-election to the Company’s Board of Directors at the Company’s upcoming 2009 Annual Meeting of Stockholders (the “Annual Meeting”) and his decision to no longer be a member of the Compensation Committee, Audit Committee or Nominating and Corporate Governance Committee, the terms of which would have commenced as of the date of the Annual Meeting held on August 26, 2009. 8.01 On August 26, 2009, the Company held its Annual Meeting. | v159165_8k.htm |
| 2009-08-14 | 8-K | 2009-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2009, Genta Incorporated issued a press release announcing financial results and corporate highlights for the second quarter and six months ended June 30, 2009. | v157790_8k.htm |
| 2009-08-12 | 8-K | 2009-08-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v157477_8k.htm |
| 2009-07-13 | 8-K | 2009-07-13 | 8.01 Other Events | 8.01 On July 13, 2009, Genta Incorporated (the “Company”) issued a press release announcing that shares of the Company’s common stock will begin trading on July 13 under the symbol GETA.OB after implementation of the Company’s previously announced one-for-fifty reverse stock split of its common stock. | v154623_8k.htm |
| 2009-07-08 | 8-K | 2009-07-07 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | v154322_8k.htm |
| 2009-06-30 | 8-K | 2009-06-29 | 8.01 Other Events | 8.01 On June 29, 2009, Genta Incorporated (the “Company”) issued a press release announcing that a previously announced reverse stock split will not be effective with the opening of trading on July 1, 2009. | v153661_8k.htm |
| 2009-06-29 | 8-K | 2009-06-26 | 8.01 Other Events | 8.01 On June 26, 2009, Genta Incorporated (the “Company”) issued a press release announcing that it had held a Special Meeting of Stockholders (the “Special Meeting”). | v153494_8k.htm |
| 2009-06-05 | 8-K/A | 2009-05-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v151556_8ka.htm |
| 2009-06-05 | 8-K/A | 2009-04-02 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | v151372_8ka.htm |
| 2009-06-01 | 8-K | 2009-06-01 | 8.01 Other Events | 8.01 On June 1, 2009, Genta Incorporated, (the Company), announced that preliminary results from its ongoing clinical study of tesetaxel, a leading oral taxane in the Company’s investigational drug portfolio. | v151227_8k.htm |
| 2009-05-29 | 8-K | 2009-05-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v151138_8k.htm |
| 2009-05-28 | 8-K | 2009-05-28 | 8.01 Other Events | 8.01 On May 28, 2009, Genta Incorporated, (the Company), announced that that it has scheduled a special meeting for stockholders of record as of May 27, 2009. | v151060_8k.htm |
| 2009-05-26 | 8-K | 2009-05-26 | 8.01 Other Events | 8.01 On May 26, 2009, Genta Incorporated, (the Company), announced that that it has postponed its special meeting of stockholders, which had previously been scheduled for 2:30 p.m., Eastern time, on Wednesday, May 27, 2009. | v150850_8k.htm |
| 2009-05-19 | 8-K | 2009-05-19 | 8.01 Other Events | 8.01 On May 19, 2009, Genta Incorporated, (the Company), announced that the independent Data Monitoring Board (DMB) for AGENDA, a randomized Phase 3 trial of Genasense® in patients with advanced melanoma, has informed the Company that the study has passed its final futility analysis for progression-free survival (PFS). | v150192_8k.htm |
| 2009-05-12 | 8-K | 2009-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2009, Genta Incorporated issued a press release announcing financial results and corporate highlights for the first quarter ended March 31, 2009. | v148795_8k.htm |
| 2009-04-29 | 8-K | 2009-04-29 | 8.01 Other Events | 8.01 On April 7, 2009, Genta Incorporated, (the Company), announced a final progress update on the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product, in patients with advanced melanoma. | v147474_8k.htm |
| 2009-04-08 | 8-K | 2009-04-07 | 8.01 Other Events | 8.01 On April 7, 2009, Genta Incorporated, (the Company), announced that the Company had completed patient enrollment into AGENDA, a Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. | v145547_8k.htm |
| 2009-04-06 | 8-K/A | 2009-04-02 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | v145343_8ka.htm |
| 2009-04-03 | 8-K | 2009-04-02 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | v145232_8k.htm |
| 2009-03-26 | 8-K | 2009-03-20 | 8.01 Other Events | 8.01 On March 20, 2009, the Superior Court of New Jersey granted the motion of Genta Incorporated (the “Company”) to dismiss the class action complaint filed against the Company, the Company’s Board of Directors and certain of the Company’s executive officers as described below. | v143964_8k.htm |
| 2009-03-12 | 8-K | 2009-03-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | y01309e8vk.htm |
| 2009-03-09 | 8-K | 2009-03-06 | 8.01 Other Events | 8.01 On March 6, 2009, Genta Incorporated, (the Company), announced that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has decided that available data are not adequate to support approval of Genasense® (oblimersen sodium) Injection for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). | y01281e8vk.htm |
| 2009-02-13 | 8-K | 2009-02-13 | 2.02 Results of Operations and Financial Condition | 2.02 On February 13, 2009, Genta Incorporated issued a press release announcing financial results and corporate highlights for the fourth quarter and year ended December 31, 2008. | y01137e8vk.htm |
| 2009-02-11 | 8-K | 2009-02-11 | 8.01 Other Events | 8.01 On February 11, 2009, Genta Incorporated, (the Company), announced that it has submitted a proposal to the Food and Drug Administration for a randomized clinical trial of tesetaxel, an oral taxane chemotherapy compound, for Special Protocol Assessment (SPA). | y01110e8vk.htm |
| 2009-02-02 | 8-K | 2009-01-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | y01038e8vk.htm |
| 2009-01-14 | 8-K | 2009-01-14 | 8.01 Other Events | 8.01 On January 14, 2009, Genta Incorporated, (the Company), announced it has initiated a new clinical trial with tesetaxel, the latest addition to Genta’s oncology product portfolio. | y00933e8vk.htm |
| 2009-01-08 | 8-K | 2009-01-08 | 8.01 Other Events | 8.01 On January 8, 2009, Genta Incorporated, (the Company), announced that two new patents related to the Company’s franchise in gallium-containing products have issued in the United States. | y00896e8vk.htm |
| 2009-01-05 | 8-K | 2009-01-05 | 8.01 Other Events | 8.01 On January 5, 2009, Genta Incorporated, (the Company), announced that that the Company has received notice from the U.S Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta’s oncology product portfolio, has been granted designation as an “Orphan Drug” for treatment of patients with advanced gastric cancer. | y00857e8vk.htm |